PURPOSE:O6-methylguanine-methyltransferase (MGMT) promoter methylation has been shown to predict survival of patients with glioblastomas if temozolomide is added to radiotherapy (RT). It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendroglial tumors (AOT). PATIENTS AND METHODS: In the European Organisation for the Research and Treatment of Cancer study 26951, 368 patients with AOT were randomly assigned to either RT alone or to RT followed by adjuvant PCV. From 165 patients of this study, formalin-fixed, paraffin-embedded tumor tissue was available for MGMT promoter methylation analysis. This was investigated with methylation specific multiplex ligation-dependent probe amplification. RESULTS: In 152 cases, an MGMT result was obtained, in 121 (80%) cases MGMT promoter methylation was observed. Methylation strongly correlated with combined loss of chromosome 1p and 19q loss (P = .00043). In multivariate analysis, MGMT promoter methylation, 1p/19q codeletion, tumor necrosis, and extent of resection were independent prognostic factors. The prognostic significance of MGMT promoter methylation was equally strong in the RT arm and the RT/PCV arm for both progression-free survival and overall survival. In tumors diagnosed at central pathology review as glioblastoma, no prognostic effect of MGMT promoter methylation was observed. CONCLUSION: In this study, on patients with AOT MGMT promoter methylation was of prognostic significance and did not have predictive significance for outcome to adjuvant PCV chemotherapy. The biologic effect of MGMT promoter methylation or pathogenetic features associated with MGMT promoter methylation may be different for AOT compared with glioblastoma.
RCT Entities:
PURPOSE:O6-methylguanine-methyltransferase (MGMT) promoter methylation has been shown to predict survival of patients with glioblastomas if temozolomide is added to radiotherapy (RT). It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendroglial tumors (AOT). PATIENTS AND METHODS: In the European Organisation for the Research and Treatment of Cancer study 26951, 368 patients with AOT were randomly assigned to either RT alone or to RT followed by adjuvant PCV. From 165 patients of this study, formalin-fixed, paraffin-embedded tumor tissue was available for MGMT promoter methylation analysis. This was investigated with methylation specific multiplex ligation-dependent probe amplification. RESULTS: In 152 cases, an MGMT result was obtained, in 121 (80%) cases MGMT promoter methylation was observed. Methylation strongly correlated with combined loss of chromosome 1p and 19q loss (P = .00043). In multivariate analysis, MGMT promoter methylation, 1p/19q codeletion, tumor necrosis, and extent of resection were independent prognostic factors. The prognostic significance of MGMT promoter methylation was equally strong in the RT arm and the RT/PCV arm for both progression-free survival and overall survival. In tumors diagnosed at central pathology review as glioblastoma, no prognostic effect of MGMT promoter methylation was observed. CONCLUSION: In this study, on patients with AOT MGMT promoter methylation was of prognostic significance and did not have predictive significance for outcome to adjuvant PCV chemotherapy. The biologic effect of MGMT promoter methylation or pathogenetic features associated with MGMT promoter methylation may be different for AOT compared with glioblastoma.
Authors: Wolfgang Wick; Christian Hartmann; Corinna Engel; Mandy Stoffels; Jörg Felsberg; Florian Stockhammer; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Richard Meyermann; Marion Rapp; Christof Meisner; Rolf D Kortmann; Torsten Pietsch; Otmar D Wiestler; Ulrike Ernemann; Michael Bamberg; Guido Reifenberger; Andreas von Deimling; Michael Weller Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Martin Glas; Caroline Happold; Johannes Rieger; Dorothee Wiewrodt; Oliver Bähr; Joachim P Steinbach; Wolfgang Wick; Rolf-Dieter Kortmann; Guido Reifenberger; Michael Weller; Ulrich Herrlinger Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: Mathilde C M Kouwenhoven; Thierry Gorlia; Johan M Kros; Ahmed Ibdaih; Alba A Brandes; Jacolien E C Bromberg; Karima Mokhtari; Sjoerd G van Duinen; Johannes L Teepen; Pieter Wesseling; Fanny Vandenbos; Wolfgang Grisold; László Sipos; Rene Mirimanoff; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Martin J van den Bent Journal: Neuro Oncol Date: 2009-12 Impact factor: 12.300
Authors: Judith W M Jeuken; Sandra J B Cornelissen; Martine Vriezen; Marieke M G Dekkers; Abdellatif Errami; Angelique Sijben; Sandra H E Boots-Sprenger; Pieter Wesseling Journal: Lab Invest Date: 2007-08-13 Impact factor: 5.662
Authors: Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran Journal: Neuro Oncol Date: 2013-11-26 Impact factor: 12.300
Authors: Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger Journal: Neuro Oncol Date: 2012-09 Impact factor: 12.300
Authors: S Trabelsi; N Mama; M Ladib; N Karmeni; M Haddaji Mastouri; M Chourabi; M Mokni; K Tlili; H Krifa; M T Yacoubi; A Saad; D H'mida Ben Brahim Journal: Clin Transl Oncol Date: 2015-08-20 Impact factor: 3.405